CytomX Therapeutics
CTMX
CTMX
68 hedge funds and large institutions have $50.7M invested in CytomX Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 20 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
0.33% more ownership
Funds ownership: 48.52% → 48.85% (+0.33%)
20% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 20
Holders
68
Holding in Top 10
–
Calls
$34K
Puts
$5K
Top Buyers
| 1 | +$613K | |
| 2 | +$299K | |
| 3 | +$197K | |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$161K |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
+$155K |
Top Sellers
| 1 | -$404K | |
| 2 | -$335K | |
| 3 | -$221K | |
| 4 |
LCM
Laurion Capital Management
New York
|
-$146K |
| 5 |
Two Sigma Advisers
New York
|
-$103K |